July 2020 - The American Medical Association is pleased that the U.S. Substance Abuse and Mental Health Services Administration and U.S. Drug Enforcement Administration (DEA) have provided increased flexibility for providing buprenorphine and methadone to patients with opioid use disorder. The AMA is further pleased at increased flexibility provided by the DEA to help patients with pain obtain necessary medications.
The AMA is greatlyconcerned by an increasing number of reports from national, state and local media suggesting increases inopioid-related mortality—particularly from illicitly manufactured fentanyl and fentanyl analogs.
"Hey Joe, you think we'll get sued for making all this fentanyl?" "Big time, Sam, you better close that garage door."